Loading clinical trials...

Evaluation of Software Enhancements to the Respironics BiPAP Auto Servo Ventilation (AutoSV) Device | Clinical Trials | Clareo Health

COMPLETEDNA

Evaluation of Software Enhancements to the Respironics BiPAP Auto Servo Ventilation (AutoSV) Device

Evaluation of Software Enhancements to the Respironics BiPAP autoSV Device

NCT00720213•Philips Respironics

View on ClinicalTrials.gov

Summary

This study is being undertaken to collect data from Respironics Inc's BiPAP Auto Servo Ventilation 3 (autoSV3) and compare with data from Respironics, Inc's BiPAP autoSV2, to confirm that the algorithms in the BiPAP autoSV3 device can safely and effectively treat participants experiencing Complex Sleep Apneas (Comp SAS) no worse than its predecessor, the BiPAP auto Servo ventilation 2 (autoSV2) device. This will be determined using a comparative, randomized design with the participants blinded to the therapy. Additionally, attempts will be made to blind the central scorer(s) with respect to which device is in use.

Detailed Description

This study was conducted to evaluate the therapeutic performance of a new auto Servo Ventilation device (Philips Respironics autoSV Advanced) for the treatment of complex central sleep apnea (CompSA). The features of autoSV Advanced include an automatic expiratory pressure (EPAP) adjustment, an advanced algorithm for distinguishing open versus obstructed airway apnea, a modified auto backup rate which is proportional to subject's baseline breathing rate, and a variable inspiratory support. Our primary aim was to compare the performance of the advanced servo-ventilator (BiPAP autoSV Advanced) with conventional servo-ventilator (BiPAP autoSV) in treating central sleep apnea (CSA). Study Design: A prospective, multicenter, randomized, controlled trial. Setting: Five sleep laboratories in the United States. Participants: Thirty-seven participants were included.

Eligibility

Age

21 - 80 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Age 21-80
•Ability to provide consent
•Documentation of medical stability by investigator
•Participants who, during the ambulatory polysomnography (PSG) study (Stardust), or in lab Diagnostic PSG demonstrated an Apnea Hypopnea Index (AHI) ≥10 or Central Apnea Index (CAI) ≥5
•or
•Participants who previously demonstrated Central sleep Apnea (CSA), with a CAI≥5 on Continuous Positive Airway Pressure (CPAP) titration.

Exclusion Criteria

•• Participants who are acutely ill, medically complicated or who are medically unstable.
•* Pregnancy (will confirm absence of pregnancy with a urine or serum pregnancy test in women of child bearing potential).
•* Participants in whom PAP therapy is otherwise medically contraindicated.
•* Participants who are unwilling to wear CPAP
•* Participants who are currently prescribed nocturnal oxygen use and are unable to forego oxygen during study nights.
•* Participants with previously diagnosed respiratory failure or respiratory insufficiency and who are known to have chronically elevated arterial carbon dioxide levels while awake (PaCO2 ≥ 45mmHg).
•* Participants who have had surgery of the upper airway, nose, sinus, or middle ear within the previous 90 days.
•* Participants with untreated, non- Obstructive Sleep Apnea (OSA)/CSA sleep disorders, including but not limited to; insomnia, periodic limb movement syndrome, or restless legs syndrome (PLM Arousal Index \> 15).
•* Participants who are unwilling to participate in the study.

Locations (5)

University of Arizona

Tucson, Arizona, United States

Arkansas Center for Sleep Medicine

Little Rock, Arkansas, United States

Mark G. Goetting

Portage, Michigan, United States

Ohio State University

Columbus, Ohio, United States

Sleepcare Diagnostics

Mason, Ohio, United States

Key Dates

Start Date

August 1, 2008

Primary Completion Date

July 1, 2009

Completion Date

July 1, 2009

Last Updated

January 29, 2019

Enrollment

ACTUAL participants

Conditions

Sleep Disordered BreathingSleep Apnea, Central

Interventions

Respironics BiPAP autoSV2

DEVICE

Respironics BiPAP autoSV3

DEVICE

Epidemiology of Sleep Disordered Breathing in Children and Young People With Cerebral Palsy

NCT06737302

Cerebral Palsy (CP)Sleep Disordered Breathing (SDB)+1 more

View study

RECRUITINGNA

Neurostimulation for Sleep Disordered Breathing

NCT06883617

Sleep Disordered Breathing (SDB)Sleep Apnea

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 29, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Evaluation of Software Enhancements to the Respironics BiPAP Auto Servo Ventilation (AutoSV) Device

Inclusion Criteria

Exclusion Criteria

Epidemiology of Sleep Disordered Breathing in Children and Young People With Cerebral Palsy

Neurostimulation for Sleep Disordered Breathing

Apnea, Stroke and Incident Cardiovascular Events

Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation

Sleep-Disordered Breathing in the Acute Phase After Stroke and Neuropsychiatric Outcomes

3D Printing of Positive Airway Pressure (PAP) Therapy Masks: a Single Site Pilot and Feasibility Study